A PHASE IV, OPEN-LABEL, NON-RANDOMISED, MULTICENTRE STUDY TO ASSESS THE LONG-TERM PERSISTENCE OF IMMUNITY TO HEPATITIS B IN ADULTS VACCINATED 20 TO 30 YEARS AGO WITH 3 OR 4 DOSES OF GSK BIOLOGICALS' HEPATITIS B VACCINE, ENGERIX-B
- Registry ID
- 116811 (HBV-322)
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE4
- Study type
- INTERVENTIONAL
- Sponsor
- GLAXOSMITHKLINE INC
- Start date
- 2016-10-17
- Last update
- 2016-09-02
Conditions
Related clinical trials
- A PHASE 3 DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL TO COMPARE THE IMMUNOGENICITY AND SAFETY OF A THREE-DOSE REGIMEN OF SCI-B-VAC TO A THREE-DOSE REGIMEN OF ENGERIX-B IN ADULTS
- A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL TO ASSESS THE LOT-TO-LOT CONSISTENCY OF SCI-B-VAC IN ADULTS
- A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER
- VACCINATING CHILDREN AFTER CHEMOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA
- A PHASE IV, OPEN-LABEL, NON-RANDOMISED, MULTI-CENTRE STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF A BOOSTER DOSE OF INFANRIX HEXA IN HEALTHY INFANTS BORN TO MOTHERS VACCINATED WITH BOOSTRIX DURING PREGNANCY OR IMMEDIATELY POST-DELIVERY
- A PHASE III, RANDOMIZED, PLACEBO-CONTROLLED, CLINICAL TRIAL TO STUDY THE SAFETY AND IMMUNOGENICITY OF THREE CONSISTENCY LOTS AND A HIGH DOSE LOT OF RVSV-ZEBOV-GP (V920 EBOLA VACCINE) IN HEALTHY ADULTS
View on source registry